The drug is currently in the clinical candidate selection stage. AND021 specifically binds to a structural domain of the transcription factor HIF-2α, blocks the heterodimerization of HIF-2α and HIF-2β to form the functional transcription factor HIF-2, and thereby downregulates the expression of HIF-2 downstream target genes. AND021 is being developed for the treatment of HIF-2-dependent renal cell carcinoma and other HIF-2-driven diseases.